Results from the SOLAR-1 trial for advanced breast cancer

Bookmark and Share
Published: 20 Oct 2018
Views: 2149
Prof Fabrice André - Institut Gustave Roussy, Paris, France

Prof Fabrice André speaks with ecancer at ESMO 2018 in Munich about results from a trial to treat advanced breast cancer with fulvestrant and targeted PI3Ka inhibitor alpelisib.

He describes how alpelisib differs from other PI3K inhibitors as it selectively targets the alpha isoform, allowing the enzyme to continue to function in other tissues.

Prof André details the improved PFS seen in the trial, with adverse events of rash and hyperglycaemia being common but manageable.

For more on these results, watch his presentation of the data at a conference session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.